Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case–control study

Gian Luca Erre¹, Alessandra Piras¹, Silvia Mura¹, Nicola Mundula¹, Marco Piras¹, Loredana Taras¹, Maria Giovanna Longu¹, Pier Sergio Saba², Antonello Ganau², Ciriaco Carru³ and Giuseppe Passiu¹

Abstract

Objective: To investigate whether levels of asymmetric dimethylarginine (ADMA), as a measure of endothelial dysfunction, are higher in patients with rheumatoid arthritis compared with healthy control subjects. The relationships between ADMA and surrogate measures of arterial stiffness were evaluated.

Methods: Patients with rheumatoid arthritis and healthy control subjects were recruited. ADMA was quantified via enzyme-linked immunosorbent assay. Arterial stiffness was evaluated using pulse wave analysis.

Results: There was no significant difference in plasma ADMA concentration between patients with rheumatoid arthritis (n = 30) and healthy controls (n = 30). Aortic augmentation pressure was significantly higher in patients than in controls. C-reactive protein and Health Assessment Questionnaire score were independent predictors of arterial stiffness in patients. There was no relationship between ADMA concentration and aortic augmentation pressure in the study population as a whole.

Conclusions: Arterial stiffness appears to be increased in rheumatoid arthritis and independently associated with systemic inflammation and physical disability. ADMA concentration was not increased in this small group of patients with rheumatoid arthritis compared with healthy controls; nor was it associated with arterial stiffness.

¹Rheumatology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria of Sassari and University of Sassari, Sassari, Italy
²Cardiology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria of Sassari and University of Sassari, Sassari, Italy
³Department of Biomedical Sciences, University of Sassari, Sassari, Italy

Corresponding author:
Gian Luca Erre, Rheumatology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria of Sassari and University of Sassari, Viale San Pietro 8, Palazzo delle Cliniche, Sassari 07100, Italy.
Email: e.gianluca@libero.it

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Aortic augmentation pressure, arterial stiffness, asymmetric dimethylarginine, ADMA, endothelial dysfunction, rheumatoid arthritis

Introduction
Arterial stiffness is influenced by endothelial dysfunction in both healthy individuals and patients with cardiovascular disease.1,2 Little is known regarding the prevalence of endothelial dysfunction and its relationship with arterial stiffness in patients with rheumatoid arthritis. The aim of the present study was to investigate whether levels of asymmetric dimethylarginine (ADMA), as a measure of endothelial dysfunction,3 are higher in patients with rheumatoid arthritis compared with healthy control subjects. In addition, the relationships between ADMA and surrogate measures of arterial stiffness were evaluated.

Patients and methods
Study population
Consecutive patients with rheumatoid arthritis who met the criteria of the American College of Rheumatology4 and had no history of cardiovascular events were enrolled from the outpatient clinic of the Rheumatology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria of Sassari and University of Sassari, Sassari, Italy, between January and May 2007. Collected data included: presence of conventional cardiovascular risk factors; treatment with aspirin, or antihypertensive or cholesterol-lowering drugs; duration of rheumatoid arthritis; steroid treatment; type and dosage of antitumour necrosis factor (TNF-α) inhibitor treatment; C-reactive protein (CRP) concentration; erythrocyte sedimentation rate; immunoglobulin M rheumatoid factor; anticyclic citrullinated peptide; Disease Activity Score (DAS);5 Ritchie Index;6 and Health Assessment Questionnaire (HAQ).7

Control subjects strictly matched for conventional cardiovascular risk factors (using echo colour Doppler carotid ultrasound), who were attending routine check-ups at the outpatient clinic of the Cardiology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria of Sassari and University of Sassari, were also enrolled. The protocol was approved by the ethics committee of the University of Sassari and all participants provided written informed consent prior to enrolment.

Study parameters
Whole blood was collected into sterile tubes containing ethylenediaminetetra-acetic acid (EDTA)-potassium, then centrifuged in a Jouan centrifuge at 1000g for 10 min, and the resulting plasma was stored at −20°C until analysis. Plasma ADMA was quantified using enzyme-linked immunosorbent assay (ELISA; DLD Diagnostika GmbH, Hamburg, Germany), according to the manufacturer’s instructions. Arterial stiffness was evaluated by pulse wave analysis as described,8 using a high-fidelity hand-held tonometry probe (Millar pressure tonometer, PWV Medical, Sydney, Australia). Registered radial pulse waveforms were recorded using a computer-based pulse wave analysis system (SphygmoCor®, PWV Medical, Sydney, Australia).

Statistical analyses
Data were presented as mean ± SD or n (%) of participants. Between-group comparisons were made using Student’s t-test, Kolmogorov–Smirnov test or χ²-test, as appropriate. Bivariante relationships were
analysed using nonparametric Spearman’s test. A two-sided $P$-value $\leq 0.05$ was considered statistically significant. Data were analysed using SPSS® version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows®.

**Results**

The study included 30 patients with rheumatoid arthritis (two male/28 female; mean age 55.0 ± 12.7 years) and 30 healthy control subjects (two male/28 female; mean age 54.1 ± 13.2 years). Demographic and clinical characteristics of the study population are shown in Table 1. There were no significant between-group differences in cardiovascular risk factors. Significantly more control subjects than patients were taking aspirin ($P = 0.04$).

Data regarding ADMA and arterial stiffness parameters are shown in Table 2.

**Table 1.** Demographic and clinical characteristics of patients with rheumatoid arthritis and healthy control subjects included in a study to investigate the relationships between asymmetric dimethylarginine concentrations and surrogate measures of arterial stiffness.

| Characteristic                          | Control group       | Rheumatoid arthritis group |
|----------------------------------------|---------------------|----------------------------|
|                                        | $n = 30$            | $n = 30$                   |
| Age, years                             | 54.1 ± 13.2         | 55.0 ± 12.7                |
| Sex, male/female                       | 2/28 (6.7/93.3)     | 2/28 (6.7/93.3)            |
| Body mass index, kg/m²                 | 25.07 ± 3.5         | 24.4 ± 4.3                 |
| Arterial hypertension                  | 6 (20.0)            | 6 (20.0)                   |
| Smoking                                | 6 (20.0)            | 6 (20.0)                   |
| Diabetes                               | 1 (3.3)             | 1 (3.3)                    |
| Total cholesterol, mg/dl               | 198.8 ± 33.0        | 196.6 ± 36.1               |
| HDL cholesterol, mg/dl                 | 60.7 ± 14.9         | 64.1 ± 17.5                |
| LDL cholesterol, mg/dl                 | 112.9 ± 65.3        | 116.9 ± 65.7               |
| Aspirin use                            | 6 (20.0)            | 1 (3.3)$^a$                |
| Lipid-lowering treatment               | 7 (23.3)            | 5 (16.7)                   |
| Hypertension treatment                 | 6 (20.0)            | 6 (20.0)                   |
| Disease duration, years                | –                   | 15.5 ± 12.4                |
| Cumulative steroids, mg prednisone equivalent | –            | 26809 ± 29315             |
| ESR, mm/h                              | –                   | 28.2 ± 19.4                |
| C-reactive protein, mg/dl              | –                   | 4.5 ± 4.0                  |
| Rheumatoid factor                      | –                   | 18 (60.0)                  |
| Anticitrullinated protein antibody     | –                   | 15 (50.0)                  |
| Methotrexate                           | –                   | 18 (60.0)                  |
| Leflunomide                            | –                   | 6 (20.0)                   |
| Etanercept                             | –                   | 11 (36.7)                  |
| Adalimumab                             | –                   | 5 (16.7)                   |
| Infliximab                             | –                   | 1 (3.3)                    |
| Ritchie Index$^6$                      | –                   | 15.8 ± 10.0                |
| Disease Activity Score$^5$             | –                   | 3.8 ± 1.4                  |
| Health Assessment Questionnaire score$^7$ | –           | 1.2 ± 0.8                  |

Data presented as mean ± SD or $n$ (%) of patients.
ESR, erythrocyte sedimentation rate; HDL, high density lipoprotein; LDL, low density lipoprotein.

$^aP = 0.04$ versus healthy controls; $\chi^2$-test.
There was no significant between-group difference in plasma ADMA concentration. Aortic augmentation pressure was significantly higher in patients than control subjects \((P = 0.02; \text{Table 2})\).

Bivariate analysis of the study population as a whole found significant associations between plasma ADMA concentration and age \((P = 0.002)\) and aortic augmentation pressure \((P = 0.015)\). Bivariate analysis of the patient group showed significant associations between ADMA concentration and cumulative steroid dose \((P = 0.025)\), Ritchie Index \((P = 0.018)\) and DAS \((P = 0.025)\), and significant associations between aortic augmentation pressure and age \((P = 0.013)\), CRP concentration \((P = 0.0001)\) and HAQ score \((P = 0.004)\). Multiple linear regression analysis found that CRP concentration and HAQ score alone were independently associated with aortic augmentation pressure in the patient group \((P = 0.0001)\).

### Discussion

Plasma ADMA concentrations were not elevated in patients with rheumatoid arthritis compared with control subjects in the present study. This is in contrast to the findings of other studies, which have reported significantly higher ADMA concentrations in treatment-naïve patients with rheumatoid arthritis, compared with controls. \(^9\) A small prospective study found a significant reduction in ADMA concentrations after 3 months’ anti-TNF-\(\alpha\) treatment. \(^10\) It is therefore possible that the absence of a significant between-group difference in ADMA concentration in the present study may be a result of long-term treatment with anti-TNF-\(\alpha\) drugs in our patient group. It should be noted that, as the range of biological variation of ADMA is extremely narrow both in health and disease, \(^11\) the sample sizes of our study and other studies might be too small to draw firm conclusions regarding ADMA concentrations.

### Table 2.

Plasma asymmetric dimethylarginine concentration and arterial stiffness parameters in patients with rheumatoid arthritis and healthy control subjects.

| Parameter                        | Control group \(n = 30\) | Rheumatoid arthritis group \(n = 30\) |
|----------------------------------|--------------------------|-------------------------------------|
| Asymmetric dimethylarginine, \(\mu\)mol/l | 0.9 ± 0.3                | 1.0 ± 0.3                           |
| Heart rate, beats per min        | 76.1 ± 8.7               | 73.9 ± 9.2                          |
| Brachial blood pressure, mmHg    |                          |                                     |
| Systolic                         | 128.2 ± 13.9             | 128.1 ± 12.4                        |
| Diastolic                        | 80.0 ± 8.2               | 75.5 ± 9.3                          |
| Mean                             | 97.5 ± 9.6               | 94.9 ± 8.8                          |
| Brachial pulse pressure, mmHg    | 48.2 ± 10.7              | 52.5 ± 11.7                         |
| Aortic blood pressure, mmHg      |                          |                                     |
| Systolic                         | 118.1 ± 13.2             | 118.5 ± 13.1                        |
| Diastolic                        | 81.3 ± 8.2               | 76.8 ± 9.2                          |
| Mean                             | 97.5 ± 9.6               | 94.9 ± 8.8                          |
| Aortic pulse pressure, mmHg      | 36.8 ± 9.2               | 41.7 ± 11.7                         |
| Aortic augmentation pressure, mmHg | 10.2 ± 5.1           | 14.3 ± 7.8*                         |
| AIx@HR75, %                      | 27.3 ± 11.3              | 32.6 ± 11.5                         |

Data presented as mean ± SD.

AIx@HR75, augmentation index normalized for heart rate of 75 beats per min.

\(^*P = 0.02\) versus healthy controls; Student’s t-test.
in rheumatoid arthritis. Furthermore, heterogeneity in ADMA quantification methods and in enrolled patient populations may further explain these apparently contradictory results.

Arterial stiffness is related to systemic inflammation and is elevated in patients with rheumatoid arthritis compared with healthy controls.12 There was a statistically significant increase in arterial stiffness in patients compared with controls in the present study. In addition, the inflammatory marker CRP was a major predictor of arterial stiffness in our patient group. We found no relationship between ADMA concentration and aortic augmentation pressure (as a measure of arterial stiffness) in either the study population as a whole or in the patient group alone. This may be due to the small sample size of our study.

In conclusion, arterial stiffness appears to be increased in rheumatoid arthritis and is independently associated with systemic inflammation and physical disability. ADMA concentration was not increased in patients with rheumatoid arthritis; nor was it associated with arterial stiffness.

Declaration of conflicting interest

The authors declare that there are no conflicts of interest.

Funding

Editorial assistance was provided by Gayle Robins on behalf of HPS–Health Publishing and Services Srl and funded by Pfizer Italia.

References

1. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. *Hypertension* 2006; 48: 602–608.
2. Jadhav UM and Kadam NN. Non-invasive assessment of arterial stiffness by pulse-wave velocity correlates with endothelial dysfunction. *Indian Heart J* 2005; 57: 226–232.
3. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation* 1998; 98: 1842–1847.
4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315–324.
5. Van der Heijde DMFM, van’t Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990; 49: 916–920.
6. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. *Q J Med* 1968; 37: 393–406.
7. Fries JF, Spitz P, Kraines RG and Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980; 23: 137–1345.
8. Erre GL, Sanna P, Zinellu A, et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. *Clin Rheumatol* 2011; 30: 21–27.
9. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. *Arthritis Rheum* 2007; 56: 809–819.
10. Spinelli FR, Di Franco M, Metere A, et al. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. *Drug Dev Res* 2014; 75(Suppl 1): S67–S69.
11. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. *Clin Chem Lab Med* 2005; 43: 1130–1138.
12. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. *Circulation* 2006; 114: 1185–1192.